| 摘要 |
Provided is a method for selecting an anti-cancer chemotherapeutic agent which includes: (a) testing a sample comprising: (i) p53 mutant cells or extracts therefrom, (ii) or cells that substantially do not express p21 and/or cells in which p21 is substantially undetectable, or an extract therefrom for the abundance of cyclin D1 protein; (b) if cyclin D1 is overexpressed and/or cyclin D1 protein is elevated, selecting a therapeutic agent comprising a taxane such as taxol; (c) if cyclin D1 is not overexpressed or cyclin D1 protein is not present at substantially elevated levels, selecting a therapeutic agent other than a taxane, such as a platinating agent for example CDDP (cis-diaminedichloroplatinum). Products can be determined by immunocytochemistry. The detection of p53 mutants by RT-PCR and cyclin D1 by western blotting is described. Screening of CDDP and taxol in clonogenic survival assays is also exemplified.
|
